Latest Breaking News On - Elderly relapsed - Page 4 : comparemela.com

Actinium Pharma (ATNM) Reports Positive 1-Year and 2-Year Overall Survival Data for Patients with Relapsed or Refractory AML

Actinium Pharma (ATNM) Reports Positive 1-Year and 2-Year Overall Survival Data for Patients with Relapsed or Refractory AML
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesNew orleansSameem abedinAvinash desaiExchange commissionErnestm morial convention centerActinium pharmaceuticals incProfessor at froedtert medical college wisconsinHans vitzthumlifesci advisorsCollege of wisconsinWall streetMedical collegeOverall survivalResponse rateAssistant professorMedical college wisconsin

Actinium Appoints Seasoned Leader Caroline Yarbrough as Chief Commercial Officer to Spearhead Iomab-B Commercialization

/PRNewswire/ Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today.

Caroline yarbroughBristol myers squibbSandesh sethHans vitzthumLifesci advisorsGoizueta business school at emory universityMerck coUniversity of delawareNijenrode universityInternational businessPeter white undergraduate research fellowshipActinium pharmaceuticals incPrnewswire actinium pharmaceuticals incPortfolio general managerGlaxo smithklineChief commercial

Actinium Announces Positive Top-line Results from Pivotal Phase 3 SIERRA Trial of Iomab-B in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia

/PRNewswire/ Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today.

United statesHans vitzthumLifesci advisorsInternational blood marrow transplant researchAmerican society of hematologyAstellas pharma incActinium pharmaceuticals incOncology incEpicentrx incSociety of hematologic oncologyMemorial sloan kettering cancer centerFred hutchinson cancer research centerActinium pharmaceuticalsElderly relapsedBone marrow transplantAbout iomab b

Actinium Expands Clinical Leadership Team to Support Key Development Programs for Iomab-B and Actimab-A

/PRNewswire/ Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today.

New yorkUnited statesMemorial sloan kettering cancer centerDrexel universityYeshiva universityMadhya pradeshMontefiore einsteinAkash naharMadhuri vusirikalaElaina haeuberHans vitzthumPatrik brodinAvinash desaiVanderbilt university medical centerPhysics at lund universityUniversity of new york

Actinium Pharmaceuticals to Participate in the 2022 Bio-Europe Conference

/PRNewswire/ Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company) a leader in the development of targeted radiotherapies, today.

Andrew olsenHans vitzthumAstellas pharma incOncology incActinium pharmaceuticals incLifesci advisorsEpicentrx incPrnewswire actinium pharmaceuticals incMemorial sloan kettering cancer centerSenior associateBusiness analysisActinium pharmaceuticalsElderly relapsedRefractory acute myeloid leukemiaAcute myeloid leukemiaAstellas pharma